News - Page 31 - Psychedelic Alpha

Read more about the article Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Post published:August 10, 2023
Post category:Press Release

Read more about the article atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Post published:August 10, 2023
Post category:Press Release

Read more about the article Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023

USA – English

USA – Polski

USA – slovenčina

USA – Français

USA – Deutsch

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023 USA – English USA – Polski USA – slovenčina USA – Français USA – Deutsch

Post published:August 9, 2023
Post category:Press Release

Read more about the article atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Post published:August 8, 2023
Post category:Press Release

Read more about the article Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders

Post published:August 8, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Post published:August 8, 2023
Post category:Press Release

Read more about the article FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010

Post published:August 8, 2023
Post category:Press Release

Read more about the article Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Post published:August 8, 2023
Post category:Press Release

Read more about the article MIND CURE ANNOUNCES CLOSING OF LNG ENERGY’S SUBSCRIPTION RECEIPT FINANCING

MIND CURE ANNOUNCES CLOSING OF LNG ENERGY’S SUBSCRIPTION RECEIPT FINANCING

Post published:August 5, 2023
Post category:Press Release

Read more about the article Natural Medicine Advisory Bulletin #2: July 2023

Natural Medicine Advisory Bulletin #2: July 2023

Post published:August 3, 2023
Post category:Colorado Natural Medicine Advisory Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.